DDX53 and neoplasm: CD4+ T cells and CD8+ T cells have been implicated in antitumor responses.30 hsBCL9z96 treatment attenuated the antitumor response in CD8+ T cells-depleted group, but not in CD4+ T cells-depleted group of CT26 tumor-bearing mice, suggesting that the antitumor responses of hsBCL9z96 treatment depends on CD8+ T cells (Supplementary Fig. 4a, b).